AUTHOR INDEX

(P = proceedings; S = supplement)

AARONS, L., VOZEH, S., WENK, M., WEISS, Ph. & FOLLATH, F. Population pharmacokinetics of tobramycin, 305

ABATZI, Th.-A. *see* STACHER, G.

ABRAM, T. S. *see* NORMAN, P.

ACTON, G. & BROOM, C. A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D_2-receptor agonist, 435

ACTON, G., BROOM, C. & HOWLAND, K. Measurement of dobutamine-induced changes in cardiac function using a novel Doppler technique, 225P

ADMIRAAL, P. J. J. *see* SCHALEKAMP, M. A. D. H.

AKINBAMI, F. O. *see* SALAKO, L. A.

AL-SEREITI, M. R., COAKES, R. L., O'SULLIVAN, D. P. D. & TURNER, P. A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye-drops in normal human volunteers, 443

AL-SEREITI, M. R., QUIK, R. F. P. & TURNER, P. The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter, 263

ALLWOOD, M. C. *see* TAN, K. K. C.

ALM, C. *see* YUE, Q. Y.

ALMOND, N. E. *see* LI KAM WA, T. C.

AMOUYAL, G. *see* LARREY, D.

ANVERSA, P. *see* SONNENBLICK, E. H.

ARIAS, T. D. & JORGE, L. F. An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbe Guaymi Amerindians of Panama, 493

ASHBY, M. J., LOYSEN, E., DI DILVIO, L. & BROWN, M. J. Comparison of haemodynamic and neuroendocrine indices of α_2-adrenoceptor function during selectivity study of efaroxan, 216P

ATIBA, J. O., BLASCHKE, T. F. & WILKINSON, G. R. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine, 161

ATKINSON, H. C. *see* BEGG, E. J.

AUCH-SCHWELK, W. *see* VANHOUTTE, P. M.

AYESH, R. *see* CHOLERTON, S.

BABANY, G. *see* LARREY, D.

BABER, N. S. *see* SCIBERRAS, D. G.

BACK, D. J. *see* KITTERINGHAM, N. R.

BACK, D. J. *see* MADDEN, S.

BACK, D. J., STEVENSON, P. & TJIA, J. F. Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes *in vitro*, 166

BACK, D. J. *see* TJIA, J. F.

BACK, D. J. *see* WILD, M. J.

BAIG, M. W., CHEE, D., GALEA, M., JACKSON, G., KENMURE, A. C. F., LITTLER, W. A., MANSY, H., PERRINS, E. J., RICHARDSON, P. D. I., TIMERICK, S. J. B., WEST, J. & WILKINSON, R. A comparison of felodipine once daily with nifedipine twice daily as additions to metoprolol in hypertension, 226

BALFOUR, D. J. K. *see* LANG, C. C.

BALL, S. E. *see* KITTERINGHAM, N. R.

BARAKA, O. Z., FORD, J. M., TRUMAN, C. A. & ROBERTS, C. J. C. Effect of propranolol on the metabolic pathways for paracetamol in man, 230P

BARCHOWSKY, A. *see* ROUTLEDGE, P. A.

BARIN, E. *see* WILKES, N. P. F.

BARNES, N. C. *see* EVANS, J. M.

BARNES, P. *see* CAMPBELL, L. M.

BARNETT, D. B. & BRECKENRIDGE, A. Editorial comment, 1S

BARROW, S. E. *see* RITTER, J. M.

BASTAIN, W. & MARLOW, H. F. The effect of age and renal impairment on the pharmacokinetics of xamoterol, 65S

BASTAIN, W. *see* NICHOLLS, D. P.

BATEMAN, D. N. *see* RASHID, M. U.

BAUCHET, J. *see* FRANSSEN, G.

BAX, N. D. S. *see* BURNS, E.

BEACHAM, J. *see* RITTER, J. M.

BEAUNE, P. *see* GED, C.

BECHTEL, P. *see* BROLY, F.

BEERMAN, C. *see* BELZ, G. G.

BEGG, E. J., ATKINSON, H. C., JEFFREY, G. M. & TAYLOR, N. W. Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations, 137

BELZ, G. G., BEERMAN, C., SCHLOOS, J. & KLEINBLOESEM, C. H. The effect of oral cilazapril and prazosin on the constrictor effects of locally infused angiotensin I and noradrenaline in human dorsal hand veins, 608

BENRIMOJ, S. I. *see* CHUA, S. S.

BENZONI, D., GEOFFROY, J., WAEBER, B., BRUNNER, H. R., BIOLLAZ, J. & SASSARD, J. Atrial natriuretic peptide and urinary prostaglandins in man, 397

BERLAN, M. *see* CHATELUT, E.

BERNARD, N. *see* FERRY, N.

BERNIER, J. J. *see* VIDON, N.

BHASKAR, N. K. *see* DANESHMEND, T. K.

BHASKAR, N. K. *see* RIMOY, G. H.

BIERI, D. *see* DAY, R. O.

BILL, K. M. *see* MCKEATING, K. T.

BIOLLAZ, J. *see* BENZONI, D.

BIONDI, M. L. *see* VANHOUTTE, P. M.

BJORNSSON, T. D. *see* DRYJSKI, M.

BLAIN, P. G. *see* WILLIAMS, F. M.

BLASCHKE, T. F. *see* ATIBA, J. O.

BORIES, P. *see* GED, C.

BRAIN, S. D., PETTY, R. G., LEWIS, J. & WILLIAMS, T. J. The effect of intradermal CGRP and histamine on blood flow in the forearm of normal volunteers and Raynaud's sufferers, 736P

BRECKENRIDGE, A. *see* BARNETT, D. B.
BRECKENRIDGE, A. M. *see* COLEMAN, M. D.
BRECKENRIDGE, A. M. *see* MILTON, K. A.
BRECKENRIDGE, A. M. *see* TJIA, J. F.
BRECKENRIDGE, A. M. *see* WINSTANLEY, P. A.
BREEN, M. *see* INGS, R. M. J.
BREIMER, D. D. *see* TE KOPPELE, J. M.
BRESSOT, N. *see* GED, C.
BRICAIRE, F. *see* FRANSSEN, G.
BRODIE, M. J. *see* MURDOCH, D.
BROLY, F., LIBERSA, C., LHERMITTE, M., BECHTEL, P. & DUPUIS, B. Effect of quinidine on the dextromethorphan *O*-demethylase activity of microsomal fractions from human liver, 29
BROOM, C. *see* ACTON, G.
BROWN, M. *see* DAY, R. O.
BROWN, M. J. *see* ASHBY, M. J.
BROWN, M. M. Effect of oxpentifylline on blood viscosity and cerebral blood flow in man, 488
BROWN, R. A. *see* LIPWORTH, B. J.
BROWNSILL, R. D. *see* INGS, R. M. J.
BRUCE, M. *see* HORN, E. H.
BRUNNER, H. R. *see* BENZONI, D.
BRUNNER, H. R. *see* BURNIER, M.
BURNIER, M., WAEBER, B., NUSSBERGER, J. & BRUNNER, H. R. Pharmacokinetics of angiotensin converting enzyme inhibitors, 133S
BURNS, E., TRIGER, D. R. & BAX, N. D. S. The prolonged elimination of indocyanine green in patients with liver disease, 733P
BUSS, D. C. *see* WARD, M. J.
BUSS, D. C., PHILLIPS, D. I. W., LITTLEY, M. D., MARSHALL, R. W., ROUTLEDGE, P. A. & LAZARUS, J. H. The effect of theophylline on thyrotoxic tremor, 103
BUTTERS, L. *see* MACDONALD, N. J.

CAIRNS, D. *see* DAY, R. O.
CAMERON, G. A. *see* SCOTT, A. K.
CAMERON, H. A., WALLER, P. C. & RAMSAY, L. E. Drug treatment of intermittent claudication, 210
CAMPBELL, I. C. *see* WIECK, A.
CAMPBELL, L. M., BARNES, P., LEES, C. T. W., MCCULLAGH, A., RICHARDSON, P. D. I., ROSS, J. R. M. & TIMERICK, S. J. B. Felodipine once daily as an addition to β-adrenoceptor antagonists in the control of hypertension, 227P
CAMPBELL, R. W. F. The management of heart failure and the scope for new therapies: what role for xamoterol?, 59S
CAPASSO, J. *see* SONNENBLICK, E. H.
CARRAI, M. *see* VIANI, A.
CASY, A. F. *see* NICHOLSON, A. N.
CHALLENOR, V. F., WALLER, D. G., HAYWARD, R. A., GRIFFIN, M. J. & ROATH, O. S. Clinical and physiological assessment of angiotensin-converting enzyme inhibition in primary Raynaud's phenomenon, 739P
CHALLENOR, V. F., WALLER, D. G., RENWICK, A. G. & GEORGE, C. F. Slow release nifedipine plus atenolol in chronic stable angina pectoris, 509
CHARLIER, A. A. *see* ROUSSEAU, M. R.
CHATELUT, E., RISPAIL, Y., BERLAN, M. & MONTASTRUC, J. L. Yohimbine increases human salivary secretion, 366
CHAUMET-RIFFAUD, P. *see* PINQUIER, J. L.
CHECKLEY, S. A. *see* WIECK, A.
CHEE, D. *see* BAIG, M. W.
CHERON, J. M. *see* GREINER, P. O.
CHOLERTON, S., AYESH, R., IDLE, J. R. & SMITH, R. L. The effect of quinine and quinidine on the metabolic ratio of debrisoquine in healthy volunteers, 732P
CHOONARA, I. A., MCKAY, P., HAIN, R. & RANE, A. Morphine metabolism in children, 599
CHRYSANT, S. G. *see* GOMEZ, H. J.
CHUA, S. S., BENRIMOJ, S. I., GORDON, R. D. & WILLIAMS, G. A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients, 369
CIROLLO, V. J. *see* GOMEZ, H. J.
CLARKE, R. S. J. *see* MCKEATING, K. T.
CLIFFORD, J. M., HOARE, R. C., JENNINGS, M., NICHOLS, J. D. & LYNN, A. G. Observations on the antagonism of clonidine-induced effects by efaroxan in healthy non-patient volunteers, 224P
CLIFFORD, J. M., HOARE, R. C., JENNINGS, M., NICHOLS, J. D. & LYNN, A. G. Safety, tolerance and disposition of efaroxan in healthy non-patient volunteers, 217P
COAKES, R. L. *see* AL-SEREITI, M. R.
COCKCROFT, J. R. *see* RITTER, J. M.
COEN, R. *see* SALETU, B.
COHEN, A. F. *see* POSNER, J.
COLEMAN, M. D., BRECKENRIDGE, A. M. & PARK, B. K. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes, 389
COLEMAN, M. D. *see* WINN, M. J.
COMBALBERT, J. *see* GED, C.
COOK, D. G. *see* TAYLOR, R. G.
COOKE, E. D. *see* LI KAM WA, T. C.
COOKE, N. J. *see* KUMAR, S.
COOPER, S. M. *see* ROBERTSON, C. S.
CORVOL, P. Closing remarks, 189S
COSTELLO, J. F. *see* EVANS, J. M.
COX, C., MILLSON, D. S., HOBSON, S. & HARRY, J. Continuous measurement of cardiac output by impedance cardiography during submaximal exercise, 227P
COX, J. P., RYAN, J., O'BRIEN, E. & O'MALLEY, K. The effect of slow-release nicardipine on ambulatory and clinic blood pressure in mild hypertension, 79
CRAIG, K. *see* MACDONALD, T. M.
CROME, P. *see* FLANAGAN, R. J.
CUISINAUD, G. *see* FERRY, N.
CURRIE, D. *see* NICHOLSON, A. N.
CURRIE, D., LEWIS, R., MCDEVITT, D. G., NICHOLSON, A. N. & WRIGHT, N. A. Central effects of the angiotensin-converting inhibitor, captopril, in healthy volunteers, 228P
CUSHMAN, D. W., WANG, F. L., FUNG, W. C., GROVER, G. J., HARVEY, C. M., SCALESE, R. J., MITCH, S. L. & DEFORREST, J. M. Comparisons *in vitro*, *ex vivo* and *in vivo* of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE), 115S
CUTHBERT, N. J. *see* NORMAN, P.

DAHLOF, C. *see* DIMENAS, E.
DALTON, N. *see* HOGG, K. J.
DANESHMEND, T. K. *see* KITCHINGHAM, G. K.
DANESHMEND, T. K., STEIN, A. G., BHASKAR, N. K. & HAWKEY, C. J. Failure of ethamsylate to reduce aspirin-induced gastric mucosal bleeding in humans, 109
DANIELSON, K. *see* HELLGREN, U.
DARRAGH, A. *see* SALETU, B.
DAVEY, P. G. *see* LANG, C. C.
DAVIES, M. K. *see* VIRK, S. J. S.
DAVIS, J. R. E. & HEATH, D. A. Comparison of different dose regimes of aminohydroxypropylidene-1-1-bisophosphonate (APD) in hypercalcaemia of malignancy, 269
DAY, M. A. E. *see* VIGHOLT SORENSON, E.
DAY, M. A. E. *see* ZECH, P. Y.
DAY, R. O., GRAHAM, G. G., BIERI, D., BROWN, M., CAIRNS, D., HARRIS, G., HOUNSELL, J., PLATT-HEPWORTH, S., REEVE, R., SAMBROOK, P. N. & SMITH, J. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers, 695
DE SOUZA, N. *see* KUMAR, S.
DEBAISIEUX, J. C. *see* ROUSSEAU, M. R.
DEFORREST, J. M. *see* CUSHMAN, D. W.
DEIGHTON, N. *see* HOGG, K. J.
DENARO, C. P. & RAVENSCROFT, P. J. Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients, 37
DERKX, F. H. M. *see* SCHALEKAMP, M. A. D. H.
DEVEREUX, K. *see* INGS, R. M. J.
DEWHURST, A. G. *see* OLIVER, R. M.
DI DILVIO, L. *see* ASHBY, M. J.
DILLON, S. *see* JAVIE, H.
DIMENAS, E., DAHLOF, C., OLOFSSON, B. & WIKLUND, I. CNS-related subjective symptoms during treatment with β_1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies, 527
DIXON, J. S., LACEY, L. F., PICKUP, M. E. & PAGE, M. C. A lack of pharmacokinetic interaction between ranitidine and piroxicam in normal subjects, 743P
DOKTOR, H. S. *see* RITTER, J. M.
DONNELLY, R., ELLIOTT, H. L., MEREDITH, P. A. & REID, J. L. Concentration-effect relationships and individual response to doxazosin in essential hypertension, 517
DRYJSKI, M., SCHNEIDER, D. E., MOJAVERIAN, P., KUO, BE-SHENG & BJORNSSON, T. D. Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations, 188
DUBOIS, J. P. *see* VIDON, N.
DUNDEE, J. W., FEE, E. & GHALY, R. G. Non-invasive electrical stimulation of P6 anti-emetic point, 231P
DUNSELMAN, P. H. J. M., EDGAR, B., SCAF, A. H. J., KUNTZE, C. E. E. & WESSELING, H. Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure, 45
DUPUIS, B. *see* BROLY, F.
DZAU, V. J. Clinical implication for therapy: possible cardioprotective effects of ACE inhibition, 183S
EADIE, M. J. *see* HOOPER, W. D.
EDGAR, B. *see* DUNSELMAN, P. H. J. M.
EDWARDS, G. *see* MILTON, K. A.
EICHELBAUM, M. *see* GROSS, A. S.
ELLERSHAW, J. *see* WARD, M. J.
ELLIOTT, H. L. *see* DONNELLY, R.
ELLIOTT, H. L. *see* SCHAFERS, R. F.
ELLMERS, S. E., NOTARIANNI, L. J. & JONES, R. W. Measured *vs* estimated creatinine clearance in immobile geriatric patients, 212P
ENG, C. *see* SONNENBLICK, E. H.
EVANS, A. M., NATION, R. L. & SANSOM, L. N. Lack of effect of cimetidine on the pharmacokinetics of R(−)- and S(+)-ibuprofen, 143
EVANS, D. F. *see* ROBERTSON, C. S.
EVANS, J. M., BARNES, N. C., ZAKRZEWSKI, J. T., SCIBERRAS, D. G., STAHL, E. G., PIPER, P. & COSTELLO, J. F. L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man, 125
EVEREST, H. *see* ROBERTSON, D. R. C.

FACTOR, S. M. *see* SONNENBLICK, E. H.
FAERGEMAN, O. *see* VIGHOLT SORENSON, E.
FEE, E. *see* DUNDEE, J. W.
FEELY, M. P. *see* KUMAR, S.
FERRY, N., BERNARD, N., POZET, N., GARDES, E., CUISINAUD, G., LABEEUW, M., ZECH, P. Y. & SASSARD, J. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate, 675
FISCHER, C. *see* GROSS, A. S.
FITZGERALD, D. E. & HARRY, J. D. Effect of β-adrenoceptor agents on the blood flow in carotid arteries in normal volunteers, 73S
FITZGERALD, D. E. Effect of xamoterol on peripheral blood vessels in healthy subjects, 70S
FLANAGAN, R. J., JOHNSTON, A., WHITE, A. S. T. & CROME, P. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage, 463
FLYNN, R. J. *see* MCKEATING, K. T.
FOLLATH, F. *see* AARONS, L.
FORD, J. M. *see* BARAKA, O. Z.
FORRESTER, L. *see* KITTERINGHAM, N. R.
FOWLES, S. E., PIERCE, D. M., PRINCE, W. T. & STANIFORTH, D. The pharmacokinetics of BRL 39123A, a novel antiherpes agent, administered by intravenous infusion to healthy subjects at dose-levels of 10, 15 and 20 mg kg^{-1}, 236P
FRANCE, L. A., GREEN, F. L. & SNOW, H. M. The effect of age, sex and treatment with xamoterol on exercise capacity in patients with heart failure, 75
FRANCIS, H. W. *see* OWEN, S. G.
FRANSSEN, G., ROUVEIX, B., LEBRAS, J., BAUCHET, J., VERDIER, F., MICHON, C. & BRICAIRE, F. Divided dose kinetics of mefloquine in man, 179
FRASER, D. G. *see* SCAVONE, J. M.
FRENEAUX, *see* LARREY, D.
FRIESEN, W. T. *see* OWEN, S. G.
FUNG, W. C. *see* CUSHMAN, D. W.

GALEA, M. *see* BAIG, M. W.
GANELLIN, C. R. *see* NICHOLSON, A. N.
GARDES, E. *see* FERRY, N.

GARDINER, P. J. *see* NORMAN, P.
GAUPMANN, G. *see* STACHER, G.
GAURON, S. *see* VIDON, N.
GED, C., ROUILLON, J. M., PICHARD, L., COMBALBERT, J., BRESSOT, N., BORIES, P., MICHEL, H., BEAUNE, P. & MAUREL, P. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction, 373
GEMMILL, J. D. *see* HOGG, K. J.
GEOFFROY, J. *see* BENZONI, D.
GEORGE, C. F. *see* CHALLENOR, V. F.
GEORGE, C. F. *see* GIBBS, S.
GEORGE, C. F. *see* ROBERTSON, D. R. C.
GEORGE, C. F. *see* WALLER, D. G.
GHALY, R. G. *see* DUNDEE, J. W.
GIBBS, S., WATERS, W. E. & GEORGE, C. F. The benefits of prescription information leaflets (2), 345
GILL, D. S. *see* SCIBERRAS, D. G.
GODBILLON, J. *see* VIDON, N.
GOLDBERG, D. J. *see* GREEN, S. T.
GOMEZ, H. J., CIROLLO, V. J., SROMOVSKY, J. A., OTTERBEIN, E. S., SHAW, W. C., RUSH, J. E., CHRYSANT, S. G., GRADMAN, A. H., LEON, A. S., MACCARTHY, E. P., NELSON, E. B., POOL, J. & VEDIN, A. Lisinopril dose-response relationship in essential hypertension, 415
GORDON, R. D. *see* GHUA, S. S.
GRADMAN, A. H. *see* GOMEZ, H. J.
GRAHAM, G. G. *see* DAY, R. O.
GRAY, A. J. *see* INGS, R. M. J.
GREEN, A. *see* HOUTMAN, P. N.
GREEN, F. L. *see* FRANCE, L. A.
GREEN, S. T., NATHWANI, D., GOLDBERG, D. J. & KENNEDY, D. H. Nabilone as effective therapy for intractable nausea and vomiting in AIDS, 494
GREENBLATT, D. J. *see* SCAVONE, J. M.
GREGORY, A. *see* TUCKER, G. T.
GREINER, P. O., ZITTOUN, J., MARQUET, J. & CHERON, J. M. Pharmacokinetics of (−)-folinic acid after oral and intravenous administration of the racemate, 289
GRIFFIN, M. J. *see* CHALLENOR, V. F.
GROSS, A. S., MIKUS, G., FISCHER, C., HERTRAMPF, R., GUNDERT-REMY, U. & EICHELBAUM, M. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype, 555
GROVER, G. J. *see* CUSHMAN, D. W.
GUNDERT-REMY, U. *see* GROSS, A. S.
GURNE, O. *see* POULEUR, H.

HABERSETZER, F. *see* LARREY, D.
HADFIELD, S. E., SLEE, S.-J. & SNOW, H. M. The cardiovascular pharmacology of xamoterol, ciclo-prolol, prenalterol and pindolol in the anaesthetised dog, 78S
HADJ-AISSA, A. *see* ZECH, P. Y.
HAIGH, J. R. M. *see* KUMAR, S.
HAIN, R. *see* CHOONARA, I. A.
HALL, S. K. *see* HOUTMAN, P. N.
HANET, C. *see* POULEUR, H.
HARRIS, G. *see* DAY, R. O.
HARRY, J. *see* COX, C.
HARRY, J. D. *see* FITZGERALD, D. E.
HARVEY, C. M. *see* CUSHMAN, D. W.
HAWKEY, C. J. *see* DANESHMEND, T. K.
HAWKEY, C. J. *see* KITCHINGHAM, G. K.
HAWKSWORTH, G. M. *see* SCOTT, A. K.
HAYWARD, R. A. *see* CHALLENOR, V. F.
HEATH, D. A. *see* DAVIS, J. R. E.
HELLGREN, U., KIHAMIA, C. M., PREMJI, Z. & DANIELSON, K. Local anaesthetic cream for the alleviation of pain during venepuncture in Tanzanian schoolchildren, 205
HENDERSON, A. H. *see* HOGAN, J. C.
HERTRAMPF, R. *see* GROSS, A. S.
HEWICK, D. S. *see* SINCLAIR, A. J.
HILEY, M. P. *see* INGS, R. M. J.
HILLIS, W. S. *see* HOGG, K. J.
HIRST, A. D. *see* WIECK, A.
HIRTZ, J. *see* VIDON, N.
HJEMDAHL, P. *see* LARSSON, P. T.
HJEMDAHL, P. *see* MARTINSSON, A.
HOARE, R. C. *see* CLIFFORD, J. M.
HOBSON, S. *see* COX, C.
HOGAN, J. C., LEWIS, M. J. & HENDERSON, A. H. *N*-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers, 421
HOGG, K. J., GEMMILL, J. D., HORNUNG, R. S., DEIGHTON, N., DALTON, N. & HILLIS, W. S. Acute and chronic cardiovascular effects of ibopamine: a neurohumoral, haemodynamic and receptor quantification study, 220P
HOOPER, W. D., WOOD, B., LANDER, C. M. & EADIE, M. J. The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin, 17
HORN, E. H. *see* MOAR, A. K.
HORN, E. H., JALLIHALL, S., BRUCE, M. & RUBIN, P. C. Treatment with atenolol and the combination of atenolol and nifedipine, and platelet behaviour in volunteers, 242P
HORNUNG, R. S. *see* HOGG, K. J.
HOSCHL, R. *see* WILKES, N. P. F.
HOUNSELL, J. *see* DAY, R. O.
HOUTMAN, P. N., HALL, S. K., GREEN, A. & RYLANCE, G. W. Rapid anticonvulsant monitoring as part of consultations in a paediatric epilepsy clinic: A study on the use of drugs, 745P
HOWARD, P. J. *see* MCKEATING, K. T.
HOWDEN, C. W. *see* TSAI, H. H.
HOWIE, C. A. *see* SCHAFERS, R. F.
HOWLAND, K. *see* ACTON, G.

IDLE, J. R. *see* CHOLERTON, S.
IDLE, J. R. *see* RIMOY, G. H.
INGS, R. M. J., GRAY, A. J., HILEY, M. P., BROWNSILL, R. D., DEVEREUX, K., BREEN, M. & MARCHANT, N. The pharmacokinetics and metabolism of [^{14}C]-fotemustine in cancer patients, 238P
IRVIN, L. E. *see* WINSTANLEY, P. A.

JACKSON, G. *see* BAIG, M. W.
JACKSON, P. R., TUCKER, G. T. & WOODS, H. F. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism—histograms and probit plots, 647

JACKSON, P. R., TUCKER, G. T. & WOODS, H. F. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism—hypothesis testing, 655
JACKSON, S. H. D. *see* LLEDO, P.
JACKSON, S. H. D. *see* NOLAN, J. A.
JALLIHALL, S. *see* HORN, E. H.
JAMES, I. *see* SCIBERRAS, D. G.
JANICKI, J. S. *see* WEBER, K. T.
JAVIE, H., KEANEY, N. P., SMY, J. R., DILLON, S. & LEE, M. Lactate excretion in sweat produced with and without pharmacological stimulation before and during steady state exercise, 746P
JAVIE, H., KEANEY, N. P., SMY, J. R., LEE, M. & DILLON, S. The excretion of lactate in human sweat stimulated by iontophoresis of pilocarpine: studies with different regions, doses and courses, 244P
JEFFREY, G. M. *see* BEGG, E. J.
JENNINGS, M. *see* CLIFFORD, J. M.
JOHNSTON, A. *see* FLANAGAN, R. J.
JOHNSTON, A. *see* LLEDO, P.
JOHNSTON, D. A. & WORMSLEY, K. G. Inhibition of gastric secretion following single morning or twice daily oral administration of sufotidine to volunteers, 403
JOHNSTON, P. C. *see* SINCLAIR, A. J.
JONES, R. W. *see* ELLMERS, S. E.
JORDAN, S. *see* SCIBERRAS, D. G.
JORGE, L. F. *see* ARIAS, T. D.
JORGENSEN, B. *see* PERRILD, H.
JUMEAU-ZIEMENDORFF, Y. *see* PIPER, C.

KAUFMANN, B. *see* PIPER, C.
KAYSER, L. *see* PERRILD, H.
KEANEY, N. P. *see* JAVIE, H.
KELLER, F. Gentamicin volume of distribution as a power function of body weight, 479
KENMURE, A. C. F. *see* BAIG, M. W.
KENNA, J. G., MARTIN, J. L. & POHL, L. R. Antibodies from patients with halothane hepatitis recognise trifluoroacetylated liver proteins, 223P
KENNEDY, D. H. *see* GREEN, S. T.
KIHAMIA, C. M. *see* HELLGREN, U.
KITCHINGHAM, G. K., PRICHARD, P. J., DANESHMEND, T. K., WALT, R. P. & HAWKEY, C. J. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine, 581
KITTERINGHAM, N. R. *see* RILEY, R. J.
KITTERINGHAM, N. R. *see* WINN, M. J.
KITTERINGHAM, N. R., BALL, S. E., TJIA, J., TINGLE, M. D., WINN, M., PARK, B. K., BACK, D. J., FORRESTER, L. & WOLF, C. R. Monooxygenase activities in human liver microsomes: comparison with cytochrome P-450 isozyme profile, 246P
KLEIJNEN, J., KNIPSCHILD, P. & TER RIET, G. Garlic, onions and cardiovascular risk factors. A review of the evidence from human experiments with emphasis on commercially available preparations, 535
KLEINBLOESEM, C. H. *see* BELZ, G. G.
KLONER, R. A. *see* PRZYKLENK, K.
KNIPSCHILD, P. *see* KLEIJNEN, J.
KOKURINA, E. V. *see* RUMIANTSEV, D. O.
KOONER, J. S., PEART, W. S. & MATHIAS, C. J. The haemodynamic and hormonal responses after clonidine occur independently of sedation in essential hypertension, 249
KOONER, J. S., RAIMBACH, S., WHITEHEAD, C., PEART, W. S. & MATHIAS, C. J. Haemodynamic responses to food ingestion in normal human subjects before and after the somatostatin analogue, octreotide (SMS 201–995), 735P
KORPELA, R. *see* OLKKOLA, K. T.
KUMAR, R. *see* WIECK, A.
KUMAR, S., PEAKER, S., DE SOUZA, N., HAIGH, J. R. M., COOKE, N. J. & FEELY, M. P. Assay of a short half-life therapeutic drug *vs* a long half-life indicator for the assessment of compliance in tuberculosis, 733P
KUMAR, S., PULLAR, T. & FEELY, M. P. The dose of phenobarbitone used to measure compliance does not seem to impair psychomotor function, 749P
KUNTZE, C. E. E. *see* DUNSELMAN, P. H. J. M.
KUO, BE-SHENG *see* DRYJSKI, M.

LABEEUW, M. *see* FERRY, N.
LABS, K.-H. Drug treatment of intermittent claudication, 208
LACEY, L. F. *see* DIXON, J. S.
LAHTELA, J. T. & SOTANIEMI, E. A. Effect of short-acting nitroglycerin on heart rate: evaluation by a self-monitoring device, 605
LAI, K. N. *see* ROBERTSHAW, M.
LAND, G. *see* POSNER, J.
LANDER, C. M. *see* HOOPER, W. D.
LANG, C. C., MORELAND, T. A. & DAVEY, P. G. Methods of assessing bioavailability of cefuroxime axetil, an oral cephalosporin, 237P
LANG, C. C., MCMURRAY, J. J., BALFOUR, D. J. K. & STRUTHERS, A. D. Atrial natriuretic factor and atriopeptin III both inhibit ACE inhibitor-induced renin release in man, 219P
LARREY, D., BABANY, G., TINEL, M., FRENEAUX, E., AMOUYAL, G., HABERSETZER, F., LETTERON, P. & PESSAYRE, D. Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients, 297
LARSSON, P. T., MARTINSSON, A., OLSSON, G. & HJEMDAHL, P. Altered adrenoceptor responsiveness during adrenaline infusion but not during mental stress; differences between receptor subtypes and tissues, 663
LAWSON, M. *see* SALAS, I. G.
LAZARUS, J. H. *see* BUSS, D. C.
LEBRAS, J. *see* FRANSSEN, G.
LEDINGHAM, S. M. *see* ROBERTSON, C. S.
LEE, M. *see* JAVIE, H.
LEES, C. T. W. *see* CAMPBELL, L. M.
LEES, K. R. *see* TSAI, H. H.
LEJEMTEL, T. H. *see* SONNENBLICK, E. H.
LEMON, M. *see* SINCLAIR, A. J.
LENNARD, M. S. *see* TUCKER, G. T.
LEON, A. S. *see* GOMEZ, H. J.
LETTERTON, P. *see* LARREY, D.
LEWIS, J. *see* BRAIN, S. D.
LEWIS, M. J. *see* HOGAN, J. C.
LEWIS, R. *see* CURRIE, D.
LHERMITTE, M. *see* BROLY, F.

LI KAM WA, T. C., ALMOND, N. E., WARD, C., COOKE, E. D. & TURNER, P. Effect of selective histamine receptor antagonists on skin response to intradermal bradykinin, 241P
LIBERSA, C. *see* BROLY, F.
LINDVALL, K. *see* MARTINSSON, A.
LIPWORTH, B. J., BROWN, R. A. & MCDEVITT, D. G. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of β_2-adrenoceptor blockade, 95
LIPWORTH, B. J., TREGASKIS, B. F. & MCDEVITT, D. G. β-adrenoceptor responses to inhaled salbutamol in the elderly, 725
LIS, Y. & WALKER, S. R. Novel medicines marketed in the UK (1960–87), 333
LITTLER, W. A. *see* BAIG, M. W.
LITTLEY, M. D. *see* BUSS, D. C.
LLEDO, P., JACKSON, S. H. D., JOHNSTON, A. & PEARSON, R. M. The analysis of debrisoquine polymorphism: an objective approach based on probability, 232P
LORENZ, R. R. *see* VANHOUTTE, P. M.
LORENZO, B. & REIDENBURG, M. M. Potential artifacts in the use of caffeine to determine acetylation phenotype, 207
LOYSEN, E. *see* ASHBY, M. J.
LYNN, A. G. *see* CLIFFORD, J. M.

MACCARTHY, E. P. *see* GOMEZ, H. J.
MACDONALD, N. J., BUTTERS, L. O'SHAUGHNESSY, D. J., RIDDELL, A. J. & RUBIN, P. C. A comparison of the effects of human alpha calcitonin gene-related peptide and glyceryl trinitrate on regional blood velocity in man, 257
MACDONALD, T. M., CRAIG, K. & WATSON, M. L. Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man, 683
MACGREGOR, G. A. *see* SUGDEN, A. L.
MACLAGAN, J. *see* TAYLOR, R. G.
MADDEN, S. & BACK, D. J. Metabolism of the contraceptive steroid norgestimate by human gut and liver *in vitro*, 743P
MADONNA, O. *see* ZECH, P. Y.
MAITRA, S. *see* SILKE, B.
MANSY, H. *see* BAIG, M. W.
MARCHANT, N. *see* INGS, R. M. J.
MARKANDU, N. D. *see* SUGDEN, A. L.
MARKS, M. N. *see* WIECK, A.
MARLOW, H. F. Xamoterol, a β_1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure, 23S
MARLOW, H. F. *see* BASTAIN, W.
MARQUET, J. *see* GREINER, P. O.
MARSHALL, R. W. & RICHENS, A. An IBM-based system for the generation, collection and analysis of saccadic and smooth pursuit eye movements, 752P
MARSHALL, R. W. *see* BUSS, D. C.
MARTIN, J. L. *see* KENNA, J. G.
MARTINSSON, A. *see* LARSSON, P. T.
MARTINSSON, A., LINDVALL, K., MELCHER, A. & HJEMDAHL, P. β-adrenergic receptor responsiveness to isoprenaline in humans: concentration-effect, as compared with dose-effect evaluation and influence of autonomic reflexes, 83
MARTSEVICH, S. YU. *see* RUMIANTSEV, D. O.
MARTYN, J. A. *see* MILLS, A. K.
MASIAH, V. *see* MEYER, F. A.
MATHER, L. E. *see* TUCKER, G. T.
MATHIAS, C. J. *see* KOONER, J. S.
MAUNUKSELA, E.-L. *see* OLKKOLA, K. T.
MAUREL, P. *see* GED, C.
MCALLISTER, G. *see* MCKEATING, K. T.
MCCANN, J. P. *see* NICHOLLS, D. P.
MCCULLAGH, A. *see* CAMPBELL, L. M.
MCDEVITT, D. G. *see* CURRIE, D.
MCDEVITT, D. G. *see* LIPWORTH, B. J.
MCDEVITT, D. G. *see* NICHOLSON, A. N.
MCINNES, G. I. *see* MURDOCH, D.
MCKAY, P. *see* CHOONARA, I. A.
MCKEATING, K. T., MCALLISTER, G., HOWARD, P. J. & CLARKE, R. S. J. Whole blood propofol concentrations during total intravenous anaesthesia, 212P
MCKEATING, K. T., BILL, K. M., FLYNN, R. J. & MOORE, J. A. Placental transfer of thiopentone and propofol following bolus administration to induce anaesthesia for elective caesarian section, 741P
MCMURRAY, J. J. *see* LANG, C. C.
MELCHER, A. *see* MARTINSSON, A.
MERCER, A. D. *see* NICHOLSON, A. N.
MEREDITH, P. A. *see* DONNELLY, R.
METELITSA, V. I. *see* RUMIANTSEV, D. O.
MEYER, F. A., YARON, I., MASHIAH, V. & YARON, M. Effect of diclofenac on prostaglandin E and hyaluronic acid production by human synovial fibroblasts stimulated with interleukin-1, 193
MICHEL, H. *see* GED, C.
MICHON, C. *see* FRANSSEN, G.
MIKUS, G. *see* GROSS, A. S.
MILLS, A. K. & MARTIN, J. A. Neuromuscular blockade with vecuronium in paediatric patients with burn injury, 155
MILLSON, D. S. *see* COX, C.
MILTON, K. A., EDWARDS, G., WARD, S. A., ORME, M. L'E. & BRECKENRIDGE, A. M. Pharmacokinetics of halofantrine in man: effects of food and dose size, 71
MITCH, S. L. *see* CUSHMAN, D. W.
MOAR, A. K., HORN, E. H. & RUBIN, P. C. Effect of eicosapentaenoic acid *in vitro* on platelet aggregation and thromboxane production in pregnancy, 243P
MOJAVERIAN, P. *see* DRYJSKI, M.
MOLHOLM HANSEN, J. *see* PERRILD, H.
MONKS, K. *see* ROBERTSON, D. R. C.
MONTASTRUC, J. L. *see* CHATELUT, E.
MOORE, J. A. *see* MCKEATING, K. T.
MOORE, U. *see* WILLIAMS, F. M.
MORELAND, T. A. *see* LANG, C. C.
MORRISON, J. F. J. & PEARSON, S. B. The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma, 545
MULDER, G. J. *see* TE KOPPELE, J. M.
MURDOCH, D., MCINNES, G. I., THOMSON, G. D., MURRAY, G. D. & BRODIE, M. J. Pharmacodynamics and pharmacokinetics of verapamil and

propranolol after single and repeated administration, 233P
MURRAY, G. D. *see* MURDOCH, D.
MUTCH, E. M. *see* WILLIAMS, F. M.

NAKAMURA, K. *see* TANAKA, E.
NASH, A. *see* WARD, M. J.
NATHWANI, D. *see* GREEN, S. T.
NATION, R. L. *see* EVANS, A. M.
NELSON, E. B. *see* GOMEZ, H. J.
NELSON, G. I. C. *see* WILKES, N. P. F.
NEWBY, S. *see* WINN, M. J.
NICHOLLS, A., PARKER, J. E. & POSNER, J. Effect of BW12C on lactate during exercise in healthy volunteers, 747P
NICHOLLS, A. J., PARKER, J. E. & POSNER, J. Increased Hb-O_2 affinity induced by BW12C in healthy volunteers: effect on heart rate, 215P
NICHOLLS, D. P., TAGGART, A. J., MCCANN, J. P., BASTIAN, W. & SHANKS, R. G. The pharmacokinetics of xamoterol in liver disease, 718
NICHOLS, J. D. *see* CLIFFORD, J. M.
NICHOLSON, A. N. *see* CURRIE, D.
NICHOLSON, A. N., PASCOE, P. A., TURNER, C., GANELLIN, C. R., CASY, A. F. & MERCER, A. D. Alertness and performance in man with enantiomers of chlorpheniramine and dimethindine, 734P
NICHOLSON, A. N., WRIGHT, N. A., ZETLEIN, M. B., CURRIE, D. & MCDEVITT, D. G. Effects of the angiotensin-converting enzyme inhibitor, captopril, on the electro-encephalogram and on body sway, 229P
NICHOLSON, E. *see* WILLIAMS, F. M.
NILSSON, J.-E. *see* NYBERG, G.
NOLAN, J. A., SHAN, K., JACKSON, S. H. D. & TURNER, P. Hospital prescribing of benzodiazepines, 752P
NORMAN, P., ABRAM, T. S., CUTHBERT, N. J. & GARDINER, P. J. The [^{3}H]-leukotriene D_4 binding site in guinea pig lung correlates with a leukotriene receptor on guinea-pig ileum, 223P
NOTARIANNI, L. J. *see* ELLMERS, S. E.
NUSSBERGER, J. *see* BURNIER, M.
NYBERG, G., NILSSON, J-E., SOLLEVI, A. & OWALL, A. The renal effects of adenosine infused in healthy volunteers over 1 to 5 h, 221P

O'BRIEN, E. *see* COX, J. P.
O'MALLEY, K. *see* COX, J. P.
O'SHAUGHNESSY, D. J. *see* MACDONALD, N. J.
O'SULLIVAN, D. P. D. *see* AL-SEREITI, M. R.
OLIVER, R. M., UPWARD, J. W., DEWHURST, A. G., RENWICK, A. G. & WALLER, D. G. Pharmacokinetics of doxazosin in patients with hypertension and renal impairment, 740P
OLKKOLA, K. T., MAUNUKSELA, E.-L. & KORPELA, R. Pharmacokinetics of intravenous buprenorphine in children, 202
OLOFSSON, B. *see* DIMENAS, E.
OLSSON, G. *see* LARSSON, P. T.
ORME, M. L'E. *see* MILTON, K. A.
ORME, M.L'E. *see* WINSTANLEY, P. A.
OTTERBEIN, E. S. *see* GOMEZ, H. J.
OWALL, A. *see* NYBERG, G.
OWEN, S. G., ROBERTS, M. S., FRIESEN, W. T. & FRANCIS, H. W. Salicylate pharmacokinetics in patients with rheumatoid arthritis, 449

PACIFICI, G. M. *see* VIANI, A.
PAGE, M. C. *see* DIXON, J. S.
PARK, B. K. *see* COLEMAN, M. D.
PARK, B. K. *see* KITTERINGHAM, N. R.
PARK, B. K. *see* RILEY, R. J.
PARK, B. K. *see* WINN, M. J.
PARKER, J. E. *see* NICHOLLS, A. J.
PARMLEY, W. W. Treatment of congestive heart failure—state of the art and future trends, 31S
PASCOE, P. A. *see* NICHOLSON, A. N.
PAULSON, O. B. *see* WALDEMAR, G.
PEAKER, S. *see* KUMAR, S.
PEARSON, R. M. *see* LLEDO, P.
PEARSON, R. M. *see* RAOOF, N. T.
PEARSON, R. M. *see* SALAS, I. G.
PEARSON, S. B. *see* MORRISON, J. F. J.
PEART, W. S. *see* KOONER, J. S.
PECK, A. W. *see* POSNER, J.
PERNENKIL, R. *see* SILKE, B.
PERRILD, H., KAYSER, L., POULSEN, H. E., SKOVSTED, L., JORGENSEN, B. & MOLHOLM HANSEN, J. Differential effect of continuous administration of β-adrenoceptor antagonists on antipyrine and phenytoin clearance, 551
PERRINS, E. J. *see* BAIG, M. W.
PESSAYRE, D. *see* LARREY, D.
PETERSON, E. L. *see* ZAROWITZ, B. J.
PETRING, O. U. The effect of oxytocin on basal and pethidine-induced delayed gastric emptying, 329
PETRING, O. U. The effect of phentolamine on basal and pethidine-induced inhibition of gastric emptying in healthy volunteers, 409
PETTY, R. G. *see* BRAIN, S. D.
PFEIFFER, A. *see* VIDON, N.
PHILLIPS, D. I. W. *see* BUSS, D. C.
PICHARD, L. *see* GED, C.
PICKUP, M. E. *see* DIXON, J. S.
PIERCE, D. M. *see* FOWLES, S. E.
PILLA, A. M. *see* ZAROWITZ, B. J.
PINQUIER, J. L., URIEN, S., CHAUMET-RIFFAUD, P. & TILLEMENT, J. P. Differences in the serum binding determinants of isradipine and darodipine—consequences for serum protein binding in various diseases, 587
PIOTROVSKII, V. K. *see* RUMIANTSEV, D. O.
PIPER, C., STAIGER, Ch., JUMEAU-ZIEMENDORFF, Y., UEBIS, V., KAUFMANN, B. & STEIN, K. Pharmacokinetics of the thromboxane A_2 receptor antagonist sulotroban (BM 13.177) in renal failure, 281
PIPER, P. *see* EVANS, J. M.
PLATT-HEPWORTH, S. *see* DAY, R. O.
POHL, L. R. *see* KENNA, J. G.
POOL, J. *see* GOMEZ, H. J.
POSNER, J. *see* NICHOLLS, A.
POSNER, J., COHEN, A. F., LAND, G., WINTON, C. & PECK, A. W. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's Syndrome), 117
POULEUR, H. *see* ROUSSEAU, M. F.
POULEUR, H., HANET, C., GURNE, O. & ROUSSEAU,

M. F. Focus on diastolic dysfunction: a new approach to heart failure therapy, 41S
POULEUR, H., HANET, C. & ROUSSEAU, M. F. The efficacy and safety of chronic oral administration of xamoterol in patients with severe heart failure treated with ACE inhibitors, 82S
POULSEN, H. E. *see* PERRILD, H.
POZET, N. *see* FERRY, N.
POZET, N. *see* ZECH, P. Y.
PREMJI, Z. *see* HELLGREN, U.
PRICHARD, P. J. *see* KITCHINGHAM, G. K.
PRINCE, W. T. *see* FOWLES, S. E.
PRZYKLENK, K. & KLONER, R. A. Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury, 167S
PULLAR, T. *see* KUMAR, S.
PULLAR, T. & WRIGHT, V. Pattern of non-steroidal anti-inflammatory drug prescribing in a teaching hospital rheumatology unit, 750P

QUIK, R. F. P. *see* AL-SEREITI, M. R.

RAIJ, L. *see* SHULTZ, P. J.
RAIMBACH, S. *see* KOONER, J. S.
RAMSAY, L. E. *see* CAMERON, H. A.
RANE, A. *see* CHOONARA, I. A.
RAOOF, N. T., PEARSON, R. M. & TURNER, P. Lithium inhibits human sperm motility *in vitro*, 715
RASHID, M. U. & BATEMAN, D. N. The effect of dobupride on stomach emptying in healthy volunteers, 748P
RAVENSCROFT, P. J. *see* DENARO, C. P.
RAWLINS, M. D. *see* WILLIAMS, F. M.
REEVE, R. *see* DAY, R. O.
REID, J. L. *see* DONNELLY, R.
REID, J. L. *see* SCHAFERS, R. F.
REID, J. L. *see* TSAI, H. H.
REIDENBURG, M. M. *see* LORENZO, B.
RENWICK, A. G. *see* CHALLENOR, V. F.
RENWICK, A. G. *see* OLIVER, R. M.
RENWICK, A. G. *see* ROBERTSON, D. R. C.
RICHARDSON, P. D. I. *see* BAIG, M. W.
RICHARDSON, P. D. I. *see* CAMPBELL, L. M.
RICHENS, A. *see* MARSHALL, R. W.
RIDDELL, A. J. *see* MACDONALD, N. J.
RILEY, R. J., KITTERINGHAM, N. R. & PARK, B. K. Structural requirements for activation of phenytoin and carbamazepine to cytotoxic metabolites *in vitro*, 239P
RILEY, R. J., KITTERINGHAM, N. R. & PARK, B. K. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites *in vitro*, 482
RIMOY, G. H., IDLE, J. R., BHASKAR, N. K. & RUBIN, P. C. The influence of food on the pharmacokinetics of 'biphasic' nifedipine at steady state in normal subjects, 612
RISPAIL, Y. *see* CHATELUT, E.
RITTER, J. M., COCKCROFT, J. R., DOKTOR, H. S., BEACHAM, J. & BARROW, S. E. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man, 573
ROATH, O. S. *see* CHALLENOR, V. F.
ROBERTS, C. J. C. *see* BARAKA, O. Z.
ROBERTS, M. S. *see* OWEN, S. G.
ROBERTSHAW, M., LAI, K. N. & SWAMINATHAN, R. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae, 275
ROBERTSON, C. S., LEDINGHAM, S. M., COOPER, S. M. & EVANS, D. F. A double-blind dose ranging study of BRL 24924 and metoclopramide on lower oesophageal sphincter pressure in healthy volunteers, 323
ROBERTSON, D. R. C., WOOD, N. D., EVEREST, H., MONKS, K., WALLER, D. G., RENWICK, A. G. & GEORGE, C. F. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa, 61
RONGIER, M. *see* VIDON, N.
ROSS, J. R. M. *see* CAMPBELL, L. M.
ROUILLON, J. M. *see* GED, C.
ROUSSEAU, M. F. *see* POULEUR, H.
ROUSSEAU, M. F., POULEUR, H., DEBAISIEUX, J. C., VAN EYLL, C. & CHARLIER, A. A. Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function, 84S
ROUTLEDGE, P. A. *see* BUSS, D. C.
ROUTLEDGE, P. A. *see* WARD, M. J.
ROUTLEDGE, P. A., STARGEL, W. W., BARCHOWSKY, A., WAGNER, G. S. & SHAND, D. G. Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction, 593
ROUVEIX, B. *see* FRANSSEN, G.
RUBIN, P. C. *see* HORN, E. H.
RUBIN, P. C. *see* MOAR, A. K.
RUBIN, P. C. *see* MACDONALD, N. J.
RUBIN, P. C. *see* RIMOY, G. H.
RUMIANTSEV, D. O., PIOTROVSKII, V. K., METELITSA, V. I., SLASTNIKOVA, I. D., MARTSEVICH, S. YU. & KOKURINA, E. V. Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy, 357
RUSH, J. E. *see* GOMEZ, H. J.
RYAN, J. *see* COX, J. P.
RYLANCE, G. W. *see* HOUTMAN, P. N.

SAARIALHO-KERE, U. Psychomotor effects of ketorolac, 495
SALAKO, L. A., SOWUNMI, A. & AKINBAMI, F. O. Pharmacokinetics of quinine in African children suffering from kwashiorkor, 197
SALAS, I. G., PEARSON, R. M. & LAWSON, M. Measurement of (+)-propranolol concentration in cervico-vaginal mucus after repeated oral administration, 243P
SALAS, I. G., PEARSON, R. M. & LAWSON, M. Lithium carbonate concentration in cervico-vaginal mucus and serum after repeated oral dose administration, 751P
SALETU, B., DARRAGH, A., SALMON, P. & COEN, R. EEG brain mapping in evaluating the time-course of the central action of DUP 996—a new acetylcholine releasing drug, 1
SALMON, P. *see* SALETU, B.
SAMBROOK, P. N. *see* DAY, R. O.
SANSOM, L. N. *see* EVANS, A. M.
SASSARD, J. *see* BENZONI, D.
SASSARD, J. *see* FERRY, N.
SAWE, J. *see* YUE, Q. Y.
SCAF, A. H. J. *see* DUNSELMAN, P. H. J. M.

SCALESE, R. J. *see* CUSHMAN, D. W.
SCAVONE, J. M., GREENBLATT, D. J. & FRASER, D. G. The bioavailability of intranasal lignocaine, 722
SCHAFERS, R. F., ELLIOTT, H. L., HOWIE, C. A. & REID, J. L. The influence of the novel α_2-adrenoceptor antagonist L-659,066 on plasma insulin and glucose levels in healthy males, 215P
SCHAFFER, J. J. *see* TREW, D. R.
SCHALEKAMP, M. A. D. H., ADMIRAAL, P. J. J. & DERKX, F. H. M. Estimation of regional metabolism and production of angiotensins in hypertensive subjects, 105S
SCHINI, V. B. *see* VANHOUTTE, P. M.
SCHIPPER, C. *see* TE KOPPELE, J. M.
SCHLOOS, J. *see* BELZ, G. G.
SCHNEIDER, C. *see* STACHER, G.
SCHNEIDER, D. E. *see* DRYJSKI, M.
SCHRAMEK, P. & WALDHAUSER, M. Dose-dependent effect and side-effect of prostaglandin E_1 in erectile dysfunction, 567
SCIBERRAS, D. G. *see* EVANS, J. M.
SCIBERRAS, D. G., GILL, D. S., JORDAN, S., JAMES, I. & BABER, N. S. Histamine release following intradermal PAF in atopic and non atopic subjects, 213P
SCOTT, A. K., CAMERON, G. A. & HAWKSWORTH, G. M. Effect of metoprolol on the pharmacokinetics of bromazepam and lorazepam, 234P
SEVER, P. S. Opening remarks, 93S
SEYMOUR, R. A. *see* WILLIAMS, F. M.
SHAN, K. *see* NOLAN, J. A.
SHAND, D. G. *see* ROUTLEDGE, P. A.
SHANKS, R. G. *see* NICHOLLS, D. P.
SHAW, W. C. *see* GOMEZ, H. J.
SHAWKET, S. *see* TAN, K. K. C.
SHULTZ, P. J. & RAIJ, L. Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations, 151S
SILKE, B., PERNENKIL, R., MAITRA, S., VERMA, S. P. & TAYLOR, S. H. A new transthoracic bioimpedance (TEI) method of cardiac output determination, 738P
SILKE, B., VERMA, S. P., PERNENKIL, R., MAITRA, S. & TAYLOR, S. H. Dose-response haemodynamics of UK 52046 in coronary disease with and without LV dysfunction, 737P
SINCLAIR, A. J., HEWICK, D. S., JOHNSTON, P. C., STEVENSON, I. H. & LEMON, M. Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity, 352
SJÖQVIST, F. *see* YUE, Q. Y.
SKOVSTED, L. *see* PERRILD, H.
SLASTNIKOVA, I. D. *see* RUMIANTSEV, D. O.
SLEE, S.-J. *see* HADFIELD, S. E.
SMITH, J. *see* DAY, R. O.
SMITH, J. C. *see* WINSTANLEY, P. A.
SMITH, R. L. *see* CHOLERTON, S.
SMITH, S. E. *see* THOMAS, S. H. L.
SMITH, S. E. *see* TREW, D. R.
SMY, J. R. *see* JAVIE, H.
SNOW, H. M. The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart, 3S
SNOW, H. M. *see* FRANCE, L. A.
SNOW, H. M. *see* HADFIELD, S. E.
SNOW, H. M. *see* VIGHOLT SORENSON, E.
SNOW, H. M. *see* ZECH, P. Y.
SOLLEVI, A. *see* NYBERG, G.
SONNENBLICK, E. H., ZHAO, M., ENG, C., LEJEMTEL, T. H., FACTOR, S. M., CAPASSO, J. & ANVERSA, P. ACE inhibitors in acute and chronic ischaemia: current status and future promise, 159S
SOTANIEMI, E. A. *see* LAHTELA, J. T.
SOWUNMI, A. *see* SALAKO, L. A.
SROMOVSKY, J. A. *see* GOMEZ, H. J.
STACHER, G., GAUPMANN, G., SCHNEIDER, C., STACHER-JANOTTA, G., STEINER-MITTELBACH, G., ABATZI, Th.-A. & STEINRINGER, H. Effects of a 5-hydroxytryptamine$_3$ receptor antagonist (ICS 205-930) on colonic motor activity in healthy men, 315
STACHER-JANOTTA, G. *see* STACHER, G.
STAHL, E. G. *see* EVANS, J. M.
STAIGER, Ch. *see* PIPER, C.
STANIFORTH, D. *see* FOWLES, S. E.
STARGEL, W. W. *see* ROUTLEDGE, P. A.
STEIN, A. G. *see* DANESHMEND, T. K.
STEIN, K. *see* PIPER, C.
STEINER-MITTELBACH, G. *see* STACHER, G.
STEINRINGER, H. *see* STACHER, G.
STEVENSON, I. H. *see* SINCLAIR, A. J.
STEVENSON, P. *see* BACK, D. J.
STOKES, G. S. *see* WILKES, N. P. F.
STRUTHERS, A. D. *see* LANG, C. C.
SUGDEN, A. L., SUGDEN, D., MARKANDU, N. D. & MACGREGOR, G. A. Protein kinase C activity in essential hypertension, 218P
SUGDEN, D. *see* SUGDEN, A. L.
SVENSSON, J.-O. *see* YUE, Q. Y.
SWAMINATHAN, R. *see* ROBERTSHAW, M.

TAGGART, A. J. *see* NICHOLLS, D. P.
TAN, K. K. C., ALLWOOD, M. C. & SHAWKET, S. Effect of ciprofloxacin on the pharmacokinetics of antipyrine, 235P
TAN, K. K. C., TRULL, A. K. & SHAWKET, S. Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction, 185
TANAKA, E. & NAKAMURA, K. The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates, 171
TAYLOR, N. W. *see* BEGG, E. J.
TAYLOR, R. G., MACLAGAN, J. & COOK, D. G. Bronchodilator action of inhaled fenoterol and ipratropium in normal subjects: a teaching exercise for medical students, 709
TAYLOR, S. H. *see* SILKE, B.
TE KOPPELE, J. M., SCHIPPER, C., BREIMER, D. D. & MULDER, G. J. Stereoselectivity in the urinary excretion of the mercapturates of R(−)- and S(−)-α-bromoisovalerylurea in man, 151
TER RIET, G. *see* KLEIJNEN, J.
THE EUROPEAN 'CORWIN' STUDY GROUP Xamoterol in mild to moderate heart failure: a subgroup analysis of patients with cardiomegaly but no concomitant angina pectoris, 67S
THOMAS, S. H. L. & SMITH, S. E. Comparative cardio-

vascular effects of nifedipine and nicardipine measured by impedance cardiography, 222P
THOMSON, A. H. *see* WATSON, I. D.
THOMSON, G. D. *see* MURDOCH, D.
TILLEMENT, J. P. *see* PINQUIER, J. L.
TIMERICK, S. J. B. *see* BAIG, M. W.
TIMERICK, S. J. B. *see* CAMPBELL, L. M.
TINEL, M. *see* LARREY, D.
TINGLE, M. D. *see* KITTERINGHAM, N. R.
TJIA, J. *see* KITTERINGHAM, N. R.
TJIA, J. F. *see* BACK, D. J.
TJIA, J. F., BACK, D. J. & BRECKENRIDGE, A. M. Calcium channel antagonists and cyclosporine metabolism: *in vitro* studies with human liver microsomes, 362
TREGASKIS, B. F. *see* LIPWORTH, B. J.
TREW, D. R., SCHAFFER, J. J., WRIGHT, L. & SMITH, S. E. Effects of topical fentanyl and naloxone on human pupillary responses, 214P
TRIGER, D. R. *see* BURNS, E.
TRULL, A. K. *see* TAN, K. K. C.
TRUMAN, C. A. *see* BARAKA, O. Z.
TSAI, H. H., LEES, K. R., HOWDEN, C. W. & REID, J. L. The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis, 53
TUCKER, G. T. *see* JACKSON, P. R.
TUCKER, G. T., MATHER, L. E., LENNARD, M. S. & GREGORY, A. Enantiomer-specific pharmacokinetics of prilocaine, 742P
TURNER, C. *see* NICHOLSON, A. N.
TURNER, P. *see* AL-SEREITI, M. R.
TURNER, P. *see* LI KAM WA, T. C.
TURNER, P. *see* NOLAN, J. A.
TURNER, P. *see* RAOOF, N. T.

UEBIS, V. *see* PIPER, C.
UPWARD, J. W. *see* OLIVER, R. M.
URIEN, S. *see* PINQUIER, J. L.

VAN EYLL, C. *see* ROUSSEAU, M. R.
VANHOUTTE, P. M., AUCH-SCHWELK, W., BIONDI, M. L., LORENZ, R. R., SCHINI, V. B. & VIDAL, M. J. Why are converting enzyme inhibitors vasodilators?, 95S
VEDIN, A. *see* GOMEZ, H. J.
VERDIER, F. *see* FRANSSEN, G.
VERMA, S. P. *see* SILKE, B.
VIANI, A., CARRAI, M. & PACIFICI, G. M. Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia, 175
VIDAL, M. J. *see* VANHOUTTE, P. M.
VIDON, N., PFEIFFER, A., GODBILLON, J., RONGIER, M., GAURON, S., HIRTZ, J., BERNIER, J. J. & DUBOIS, J. P. Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: application of diclofenac, 121
VIGHOLT SORENSON, E., FAERGEMAN, O., DAY, M. A. E. & SNOW, H. M. Long-term efficacy of xamoterol (a β_1-adrenoceptor partial agonist) in patients with mild to moderate heart failure, 86S
VIRK, S. J. S. & DAVIES, M. K. Effects of xamoterol in resting and exercise haemodynamics in patients with chronic heart failure, 15S
VOZEH, S. *see* AARONS, L.

WAEBER, B. *see* BENZONI, D.
WAEBER, B. *see* BURNIER, M.
WAGNER, G. S. *see* ROUTLEDGE, P. A.
WALDEMAR, G. & PAULSON, O. B. Angiotensin converting enzyme inhibition and cerebral circulation, 177S
WALDHAUSER, M. *see* SCHRAMEK, P.
WALKER, S. R. *see* LIS, Y.
WALLER, D. G. & GEORGE, C. F. Prodrugs, 497
WALLER, D. G. Long-term studies with xamoterol in heart failure, 53S
WALLER, D. G. *see* CHALLENOR, V. F.
WALLER, D. G. *see* OLIVER, R. M.
WALLER, D. G. *see* ROBERTSON, D. R. C.
WALLER, P. C. *see* CAMERON, H. A.
WALT, R. P. *see* KITCHINGHAM, G. K.
WANG, F. L. *see* CUSHMAN, D. W.
WARD, C. *see* LI KAM WA, T. C.
WARD, M. J., BUSS, D. C., ELLERSHAW, J., NASH, A. & ROUTLEDGE, P. A. Bioavailability of intranasal metoclopramide, 616
WARD, S. A. *see* MILTON, K. A.
WATERS, W. E. *see* GIBBS, S.
WATSON, I. D. & THOMSON, A. H. The value of therapeutic drug monitoring to the practising physician—an hypothesis needing sensible application, 619
WATSON, M. L. *see* MACDONALD, T. M.
WEBER, K. T. & JANICKI, J. S. Angiotensin and the remodelling of the myocardium, 141S
WEISS, Ph. *et al.*, AARONS, L.
WENK, M. *see* AARONS, L.
WESSELING, H. *see* DUNSELMAN, P. H. J. M.
WEST, J. *see* BAIG, M. W.
WHELPTON, R. Sulphadimidine acetylator status determined at two dose levels, 240P
WHITE, A. S. T. *see* FLANAGAN, R. J.
WHITEHEAD, C. *see* KOONER, J. S.
WIECK, A., HIRST, A. D., MARKS, M. N., CHECKLEY, S. A., CAMPBELL, I. C. & KUMAR, R. The growth hormone response to the dopamine agonist apomorphine is enhanced in women at high risk of puerperal psychosis, 748P
WIKLUND, I. *see* DIMENAS, E.
WILD, M. J. & BACK, D. J. Inhibition of oestrogen 2-hydroxylase activity of human liver microsomes by cimetidine *in vitro*: effect of preincubation, 744P
WILKES, N. P. F., BARIN, E., HOSCHL, R., STOKES, G. S. & NELSON, G. I. C. Comparison of the immediate and long-term effects of captopril and isosorbide dinitrate as adjunctive treatment in mild heart failure, 427
WILKINSON, G. R. *see* ATIBA, J. O.
WILKINSON, R. *see* BAIG, M. W.
WILLIAMS, F. M., MOORE, U., SEYMOUR, R. A., MUTCH, E. M., NICHOLSON, E., WRIGHT, P. A. WYNNE, H., BLAIN, P. G. & RAWLINS, M. D. Benorylate hydrolysis by human plasma and human liver, 703
WILLIAMS, G. *see* CHUA, S. S.
WILLIAMS, T. J. *see* BRAIN, S. D.
WINN, M. *see* KITTERINGHAM, N. R.
WINN, M. J., KITTERINGHAM, N. R., COLEMAN, M. D., NEWBY, S. & PARK, B. K. The effects of

lomofloxacin on cytochrome P-450 mediated drug metabolism in human liver microsomes, 238P
WINSTANLEY, P. A. & ORME, L'E. M. The effects of food on drug bioavailability, 621
WINSTANLEY, P. A., IRVIN, L. E., SMITH, J. C., ORME, M. L'E. & BRECKENRIDGE, A. M. Adverse drug reactions: a hospital pharmacy-based reporting scheme, 113
WINTON, C. *see* POSNER, J.
WOLF, C. R. *see* KITTERINGHAM, N. R.
WOOD, B. *see* HOOPER, W. D.
WOOD, N. D. *see* ROBERTSON, D. R. C.
WOODS, H. F. *see* JACKSON, P. R.
WORMSLEY, K. G. *see* JOHNSTON, D. A.
WRIGHT, L. *see* TREW, D. R.
WRIGHT, N. A. *see* CURRIE, D.
WRIGHT, N. A. *see* NICHOLSON, A. N.
WRIGHT, P. A. *see* WILLIAMS, F. M.
WRIGHT, V. *see* PULLAR, T.
WYNNE, H. *see* WILLIAMS, F. M.

YARON, I. *see* MEYER, F. A.
YARON, M. *see* MEYER, F. A.
YEO, W. W. Persistent cough with enalapril: reported incidence depends on method used, 245P
YUE, Q. Y., SVENSSON, J.-O., ALM, C., SJOQVIST, F. & SAWE, J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine, 629
YUE, Q. Y., SVENSSON, J.-O., ALM, C., SJOQVIST, F. & SAWE, J. Codeine *O*-demethylation co-segregates with polymorphic debrisoquine hydroxylation, 639

ZAKRZEWSKI, J. T. *see* EVANS, J. M.
ZAROWITZ, B. J., PILLA, A. M. & PETERSON, E. L. Bioelectrical impedance modelling of gentamicin pharmacokinetic parameters, 471
ZECH, P. Y. *see* FERRY, N.
ZECH, P. Y., POZET, N., DAY, M. A. E., SNOW, H. M., MADONNA, O. & HADJ-AISSA, A. Effects of xamoterol on sodium excretion in volunteers, 89S
ZETLEIN, M. B. *see* NICHOLSON, A. N.
ZHAO, M. *see* SONNENBLICK, E. H.
ZITTOUN, J. *see* GREINER, P. O.

SUBJECT INDEX

(P = proceedings; S = supplement)

α-adrenoceptors, 663
α_1-acid glycoprotein, 587
α_1-adrenoceptor antagonist, 215P, 216P, 737P
α_1-adrenoceptor blockers, 608
α-bromoisovalerylurea, 608
ACE inhibition, 183S, 683, 739P
ACE inhibitor, 53, 219P, 228P, 229P, 415
ACE inhibitors, 82S, 115S, 135S, 159S, 608
Absorption, 71, 188
Acetylation phenotype, 207
Acetylator status, 240P
Acetylcholine, 151S
Acetylcholine releasing nootropic, 1
Activation, 389
Acupuncture, 231P
Adenosine, 221P
Adrenergic neurotransmission, 95S
Adverse drug reaction reports, 113
Adverse effects, 281
Age, 61, 725
AIDS, 494
Ambulatory blood pressure measurements, 79
Aminoglycoside, 137
Aminoglycosides, 37
Aminohydroxypropylidene-1,1-bisphos, 269
Anaesthesia, 155
Anaesthesia, intravenous, 212P
Angina pectoris, 509
Angiotensin, 141S
Angiotensin I, 608
Angiotensin II, 177S
Angiotensin conversion, 105S
Angiotensin converting enzyme, 105S, 177S
Angiotensin converting enzyme inhibitor, 415
Angiotensin metabolism, 105S
Anti-emetic, 494
Anti-emetic point, 231P
Antibiotics, 223P
Antibody fragments, 353
Anticonvulsant monitoring, 745P
Antiherpes agent, 236P
Antimalarial, 71
Antimycotics, 166
Antipyrine, 171, 235P, 551
Apomorphine, 748P
Aspirin, 573, 581
Asthma, 545
Atenolol, 95, 242P, 509, 527, 551
Atopic subjects, 213P
Atrial natriuretic peptide, 219P, 397
Atriopeptin III, 219P
Atropine, 83
Autoregulation, 177S

β-adrenoceptor, 725
β-adrenoceptor antagonist, 95, 227
β-adrenoceptor blockers, 527
β-adrenoceptors, 83, 663
β_1-adrenoceptor, 3S, 15S, 23S, 41S
6β-hydroxycortisol, 373
Benorylate, 703
Benzodiazepines, 752P
Bimodality testing, 655
Bioactivation, 482
Bioavailability, 71, 237P, 616, 621, 722
Bioelectrical impedance analysis, 471
Black children, 205
Blood flow, 70S
Blood pressure, 257, 369
Blood viscosity, 488
BM 13.177, 281
Body sway, 229P
Bradykinin, 95S, 241P, 573
BRL 24924, 323
BRL 39123A, 236P
Bromazepam, 234P
Bromocriptine, 443
Bronchoconstriction, 125
Bronchodilators, 709
Buprenorphine, 202
Burns, 155
BW12C, 215P, 747P

CGRP, 257, 736P
CNS effects, 229P
Caffeine, 207
Calcitonin gene related peptide, 736P
Calcium channel antagonists, 362
Calcium channel blockers, 79
Captopril, 151S, 167S, 228P, 229P, 427
Carbamazepine, 239P, 482
Carbidopa, 61
Cardiac output, 227P, 738P
Cardiomegaly, 67S
Cardioprotection, 183S
Cardioselectivity, 95
Cardiovascular disease, 535
Cardiovascular pharmacology, 183S
Cardiovascular reflexes, 83
Carotid arteries, 70S
Caucasians, 629
Cefuroxime, 237P
Cephalosporin, 237P
Cerebral blood flow, 177S, 488
Cerebrovascular disease, 488
Cervico-vaginal mucus, 243P, 751P
Children, 202, 599
Chinese, 629
Chlorpheniramine, 734P
Chronic stable angina pectoris, 509
Chronic treatment, 449
Ciclopirolol, 78S

Cilazapril, 608
Cimetidine, 143, 171, 744P
Ciprofibrate, 675
Ciprofloxacin, 185, 235P
Circadian rhythm, 545
Cirrhosis, 53
Clonidine, 83, 224P, 249
Closing remarks, 189S
Codeine, 639
Codeine metabolism, 629
Commercial preparations, 535
Communication knowledge, 345
Compliance, 733P, 749P
Concentration effect, 517
Congestive heart failure, 31S
Contraceptive steroid, 743P
Coronary disease, 737P
Coronary reperfusion, 167S
Cough, 245P
Creatinine clearance, 212P, 275
Cyclic AMP, 83
Cyclosporin, 185, 362
Cytochrome P 450, 166, 238P, 246P, 373

Dapsone, 389
Darodipine, 587
Deafness, 695
Debrisoquine, 161, 232P, 493, 639, 732P
Debrisoquine-type polymorphism, 29
Demethylation, 629
Development time, 333
Dextromethorphan, 29, 297
Dextropropoxyphene, 463
Diclofenac, 121, 193
Digoxin toxicity, 352
Dimethindene, 734P
Dobupride, 748P
Dobutamine, 225P
Dopamine, 683, 748P
Dopamine agonist, 435
Dopaminergic agonists, 263, 443
Doppler, 257
Doppler technique, 225P
Dose-response relationship, 415
Doxazosin, 517, 740P
Drug interaction, 143
Drug interactions, 185
Drug metabolism, 238P
DUP 996, 1

EDRF, 151S
EEG brain mapping, 1
Eicosopentenoic acid, 243P
Efaroxan, 216P, 217P, 224P
Effective patent life, 333
Elderly volunteers, 463
Electroencephalogram, 229P
EMLA, 205
Enalapril, 151S, 167S, 245P
Enantiomers, 555
Enantiomer specific, 742P
Endothelium-derived contracting factor, 95S
Endothelium-derived relaxing factor, 95S
Epilepsy, 745P
Ethamsylate, 109
Ethnic differences, 629

Felodipine, 45, 226P, 227P
Fentanyl, 214P
Fibroblasts, 193
Flecainide, 555
(–)-folinic acid, 289
Food, 612, 621
Fotemustine, 238P
Free digoxin, 352
Free drug concentration, 593
Frusemide, 175, 683

GFR, 275
Garlic, 535
Gastric absorption, 121
Gastric bleeding, 581
Gastric emptying, 121, 329, 409, 748P
Gastric mucosal bleeding, 109
Gastric secretion, 403
General practice, 345
Genetic polymorphism, 493
Gentamicin, 137, 479
Gentamicin pharmacokinetics, 471
Glucuronidation, 599, 629
Glutathione conjugation, 151
Glycerol, 83
Glyceryl trinitrate, 257, 421
Growth hormone, 748P

H_2-receptor antagonist, 403
Haemodialysis, 675
Haemodynamics, 249, 737P
Haemostatic agent, 109
Halofantrine, 71
Halothane, 223P
Heart failure, 15S, 23S, 41S, 45, 53S, 59S, 67S, 75S, 82S, 86S, 159S, 427
Heparin, 188
Hepatic disorders, 587
Hepatic insufficiency, 587
Hepatitis, 223P
Histamine, 125, 213P, 736P
Histamine receptor antagonist, 241P
Histograms, 647
Hormonal, 249
Hospital patients, 113
Hospital prescribing, 752P
5-HT_3 receptor antagonist, 315
Human, 389
Human colonic motor activity, 315
Human liver, 166, 362, 373, 703
Human psychopharmacology, 1
Humans, 662
Hyaluronic acid, 193
Hydralazine, 151S
Hydroxylation, 639
Hypercalcaemia, 269
Hypertension, 79, 218P, 226P, 227P, 415, 517, 740
Hypertensive patients, 369
Hyperthyroidism, 103

Ibopamine, 220P
Ibuprofen enantiomers, 143
ICS 205-930, 315
Impedance cardiography, 222P, 227P
Individualised dosing, 137

Indocyanine green, 171, 733P
Induction, 373
Inflammatory disorders, 587
Information leaflets, 345
Inhibition of drug metabolism, 161
Inhibition of metabolism, 362
Innovation, 333
Insulin, 215P
Interaction, 743P
Interleukin-1, 193
Intermittent claudication, 208, 210
Intranasal, 722
Intraocular pressure, 263, 443
Intubation, 121
Ischaemic heart disease, 84S, 357, 605
Isoprenaline, 83
Isosorbide dinitrate, 427
Isradipine, 587

Ketoconazole, 161, 166
Ketorolac, 495
Kidney, 397, 683
Kwashiorkor, 197

L-648,051, 125
L-659,066, 215P
Lactate, 244P, 746P, 747P
Lamotrigine, 117
Left ventricular diastolic function, 84S
Leukotriene D_4, 223P
Levodopa, 61
Lignocaine, 593, 722
Lisinopril, 415
Lithium, 715, 751P
Liver, 389
Liver disease, 175, 297, 718, 733P
Local anaesthesia, 205
Local angiotensin production, 105S
Lomofloxacin, 238P
Long term efficacy, 86S
Lorazepam, 234P
Lower oesophageal sphincter pressure, 323
LTD_4 antagonist, 125

Malaria, 179
Malignant disease, 269
Man, 639
Mephenytoin, 161
Mephloquine, 179
Metabolism, 555
Metoclopramide, 323, 616
Metoprolol, 226P, 234P, 527, 551
Michaelis-Menten constants, 449
Michaelis-Menten parameters, 17
Monooxygenase activity, 24P
Morphine, 599
Myocardial infarction, 593
Myocardium, 141S
Myocyte loss, 159S

Nabilone, 494
N-acetylcysteine, 421
Naloxone, 214P
Nasal decongestants, 369
Natriuresis, 397
Neonates, 599
Neuromuscular, 155
New chemical entity, 333
Ngawbe Guaymi Amerindians, 493
Nicardipine, 79, 222P
Nifedipine, 222P, 226P, 242P, 357, 509, 612
Nitrazepam, 249
Nitroglycerin, 605
Non-atopic subjects, 213P
Non-contact tonometer, 263, 443
Non-steroidal anti-inflammatory, 750P
Noradrenaline, 608
Nordextropropoxyphene, 463
Norgestimate, 743P
Normal subjects, 709

O-demethylation, 639
Octreotide, 735P
Oestrogen 2-hydroxylase, 744P
Onions, 535
Opening remarks, 93S
Ototoxicity, 695
Oxidation capacity, 297
Oxidation phenotyping, 297
Oxpentifylline, 488
Oxytocin, 329

PAF, 213P
Paediatrics, 155
Pain, 205
Paracetamol, 230P, 703
Partial agonist, 3S, 15S, 23S, 41S
Patient satisfaction, 345
Performance, 734P
Pergolide, 263
Perindopril, 53
Peripheral blood flow, 70S
Pethidine, 329, 409
Pharmaceutical industry, 333
Pharmacodynamics, 1, 53, 233P
Pharmacogenetics, 639
Pharmacokinetic modelling, 471
Pharmacokinetics, 17, 37, 45, 53, 61, 65S, 71, 117, 135S, 137, 143, 179, 185, 188, 197, 202, 233P, 234P, 235P, 236P, 238P, 281, 289, 449, 463, 517, 555, 612, 675, 718, 740P, 742P, 743P
Phenobarbitone, 749P
Phentolamine, 409
Phenytoin, 17, 239P, 482, 551
Pilocarpine, 244P
Pindolol, 78S, 84S
Piroxicam, 743P
Placental transfer, 741P
Plasma, 703
Plasma creatinine, 275
Plasma protein binding, 175
Plasma renin, 105S
Polymorphic drug metabolism, 547, 655
Polymorphism, 232P, 493, 639
Population pharmacokinetics, 305
Power function, 479
Prazosin, 608
Pregnancy, 17, 243P
Prenalterol, 78S
Prilocaine, 742P

Probit plots, 647
Prodrugs, 497
Prokinetic agent, 323
Prolactin, 435
Propofol, 212P, 741P
(+)-propranolol, 244P
Propranolol, 95, 230P, 233P, 551, 725
Prostacyclin, 95S, 573
Prostaglandin E, 193
Prostaglandin metabolites, 573
Prostaglandins, 397, 573, 683
Protein binding, 357, 587, 593
Protein kinase C, 218P
Pseudoephedrine, 369
Psychomotor effects, 495
Psychomotor performance, 749P
Puerperal psychosis, 748P
Pupillary responses, 214P

Quinidine, 732P
Quinidine inhibition, 29
Quinine, 197, 732P

Radioligand binding, 663
Radionuclides, 329, 409
Ramipril, 683
Ranitidine, 581, 743P
Raynaud's phenomenon, 739P
Raynaud's disease, 736P
Renal function, 65S
Renal effects, 221P
Renal failure, 281
Renal function, 89S
Renal impairment, 740P
Renal insufficiency, 675
Renin, 219P
Renin angiotensin system, 183S
Reperfusion injury, 167S
Rheumatoid arthritis, 449
Rifampicin, 373
Roxatidine acetate, 171

Saccadic eye movements, 722P
Salbutamol, 95, 725
Salicylate, 695, 703
Salicylic acid, 449
Salicyluric acid, 449
Salivary secretion, 366
Sedation, 249
Semisolids, 329, 409
Shear stress, 95S
Side effects, 315
Single-dose study, 449
Slow release nifedipine, 509
SK&F 101468, 435
Smooth pursuit eye movements, 752P
SMS 201-995, 735P
Sodium excretion, 89S
Sodium nitroprusside, 151S
Somatostatin analogue, 735P
Sparteine, 493
Sparteine polymorphism, 555
Sperm motility, 715
Spontaneously hypertensive rats, 115S
Stable isotope, 17
Stereoselectivity, 151
Structural requirements, 482
Student practical, 709
Stunned myocardium, 158S, 167S
Sufotidine, 403
Sulotroban (BM 13.177), 281
Sulphadimidine, 240P
Sweat, 746P
Sympatholytic, 249

Terbinafine, 166
Theophylline, 103
Therapeutic drug monitoring, 305, 619
Thiopentone, 741P
Thromboxane, 243P
Thromboxane A_2, 573
Thromboxane A_2 receptor antagonist, 281
Time-course, 1
Timolol, 443
Tinnitus, 695
Tissue distribution, 115S
Tobramycin, 137, 305
Tolerability, 1
Tolerance, 421
Transthoracic bioimpedance method, 738P
Tremor, 103
Trimethadione, 171
Type A personality, 527

UK 52046, 737P
Unbound drug, 695

Vagal activity, 545
Veins, 608
Venepuncture, 205
Ventricular remodelling, 159S
Verapamil, 233P, 357
Volume of distribution, 479

Well-being, 527

Xamoterol, 3S, 15S, 23S, 31S, 41S, 53S, 59S, 65S, 67S, 70S, 73S, 75S, 78S, 82S, 84S, 86S, 89S, 718

Yohimbine, 366